Uso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico

dc.creatorSabugo S,Francisca
dc.creatorLlanos M,Carolina
dc.creatorSoto S,Lilian
dc.creatorGutiérrez,Jorge
dc.creatorCuchacovich T,Miguel
dc.date2005-06-01
dc.date.accessioned2017-03-07T15:26:40Z
dc.date.available2017-03-07T15:26:40Z
dc.identifierhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000600010
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/385185
dc.descriptionNew therapeutic approaches that include depletion of B cells using rituximab, a chimeric monoclonal antibody directed against the B cell specific antigen CD-20 have been developed for the treatment of systemic lupus erythematosus (SLE). We report the case of a 18 years old girl with SLE that did not respond and experienced adverse effects with the use of hydroxycloroquine, methotrexate, mycophenolate mofetil, azathioprine and high-dose steroids. Rituximab was given weekly at 375 mg/m² for four doses. The drug was well tolerated and the patient had no adverse reactions. She remains asymptomatic three months later
dc.formattext/html
dc.languagees
dc.publisherSociedad Médica de Santiago
dc.sourceRevista médica de Chile v.133 n.6 2005
dc.subjectLupus erythematosus, systemic
dc.subjectMonoclonal antibody CD20
dc.subjectRituximab
dc.titleUso del rituximab(anticuerpo monoclonal anti-CD20) en lupus eritematoso sistémico refractario a tratamiento: Caso clínico
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución